The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
127372271 12737227 1 I 2011 20160908 20160913 20160913 EXP US-LANNETT COMPANY, INC.-US-2016LAN001622 LANNETT JORDAN HILL, JENNA SHIELDS AND VIDA PASSERO. TYROSINE KINASE INHIBITOR-ASSOCIATED SYNDROME OF INAPPROPRIATE SECRETION OF ANTI-DIURETIC HORMONE. J ONCOL PHARM PRACTICE. 2016;22 (5):729-732 0.00 Y 0.00000 20160913 OT US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
127372271 12737227 1 PS RABEPRAZOLE SODIUM. RABEPRAZOLE SODIUM 1 UNK U 90678
127372271 12737227 2 SS IMATINIB IMATINIB 1 400 MG, QD 0 400 MG
127372271 12737227 3 SS IMATINIB IMATINIB 1 400 MG, QD 0 400 MG
127372271 12737227 4 SS IMATINIB IMATINIB 1 300 MG, QD 0 300 MG
127372271 12737227 5 SS IMATINIB IMATINIB 1 400 MG, QD 0 400 MG
127372271 12737227 6 SS DASATINIB DASATINIB 1 100 MG, QD 0 100 MG
127372271 12737227 7 SS NILOTINIB NILOTINIB 1 400 MG, BID 0 400 MG
127372271 12737227 8 SS NILOTINIB NILOTINIB 1 400 MG, QD 0 400 MG
127372271 12737227 9 SS BOSUTINIB BOSUTINIB 1 500 MG, QD 0 500 MG
127372271 12737227 10 SS BOSUTINIB BOSUTINIB 1 500 MG, 3 DAYS A WEEK 0 500 MG
127372271 12737227 11 SS BOSUTINIB BOSUTINIB 1 200 MG, QD 0 200 MG
127372271 12737227 12 SS BOSUTINIB BOSUTINIB 1 300 MG, QD 0 300 MG
127372271 12737227 13 C DIAZEPAM. DIAZEPAM 1 UNK U 0
127372271 12737227 14 C FINASTERIDE. FINASTERIDE 1 UNK U 0
127372271 12737227 15 C TAMSULOSIN TAMSULOSIN 1 UNK U 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
127372271 12737227 1 Product used for unknown indication
127372271 12737227 2 Chronic myeloid leukaemia
127372271 12737227 6 Chronic myeloid leukaemia
127372271 12737227 7 Product used for unknown indication
127372271 12737227 9 Chronic myeloid leukaemia
127372271 12737227 13 Product used for unknown indication
127372271 12737227 14 Product used for unknown indication
127372271 12737227 15 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
127372271 12737227 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
127372271 12737227 Drug effect increased
127372271 12737227 Drug interaction
127372271 12737227 Inappropriate antidiuretic hormone secretion

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
127372271 12737227 2 201011 201102 0
127372271 12737227 3 201111 201201 0
127372271 12737227 4 201201 201307 0
127372271 12737227 5 201308 201312 0
127372271 12737227 6 201102 201107 0
127372271 12737227 7 201109 0
127372271 12737227 8 201110 0
127372271 12737227 9 201312 0
127372271 12737227 10 201401 201401 0
127372271 12737227 11 201402 201405 0
127372271 12737227 12 201405 0